Log In
BCIQ
Print this Print this
 

LS-008

  Manage Alerts
Collapse Summary General Information
Company Changzhou Le Sun Pharmaceuticals Ltd.
DescriptionPhosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (PLK1; STPK13) dual inhibitor
Molecular Target Phosphoinositide 3-kinase (PI3K) ; Polo-like kinase 1 (PLK1) (STPK13)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerSuzhou Yabao Pharmaceutical R&D Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today